PD-1 inhibitor
Showing 1 - 25 of >10,000
Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)
Recruiting
- Nasopharyngeal Carcinoma
- Anti-EGFR and PD-1 inhibitor arm
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Nov 26, 2023
Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Tumors Trial in Guangzhou (Pemigatinib, PD-1 Inhibitors)
Recruiting
- Carcinoma
- +4 more
- Pemigatinib
- PD-1 Inhibitors
-
Guangzhou, Guangdong, ChinaLei Zhang
Jun 21, 2023
Head Neck Cancer, Intratumoral Injection Trial in Chicago (RiMO-301)
Recruiting
- Head Neck Cancer
- Intratumoral Injection
-
Chicago, IllinoisUniversity of Illinois at Chicago
Apr 28, 2023
Esophageal Tumor Metastatic, Esophageal Cancer Stage IVb Trial in Beijing (drug, biological, radiation)
Recruiting
- Esophageal Neoplasm Metastatic
- Esophageal Cancer Stage IVb
- TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
- +3 more
-
Beijing, Beijing, ChinaCancer hospital, CAMS
Oct 19, 2023
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and
Not yet recruiting
- Colorectal Neoplasms
-
Beijing, Xicheng Dis, ChinaBeijing Friendship Hospital, Capital medical University
Sep 5, 2023
HNSCC, Radiotherapy, PD-1 Trial in Guangzhou (PD-1inhibitor, concurrent chemoradiotherapy)
Recruiting
- HNSCC
- +2 more
- PD-1inhibitor
- concurrent chemoradiotherapy
-
Guangzhou, Guangdong, ChinaSun yat-sen memorial hospital
Aug 6, 2023
NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Alirocumab and Cemiplimab
- (no location specified)
Jan 31, 2023
Hepatocellular Carcinoma Trial in Beijing (iNKT Cells, PD-1, Regorafenib)
Not yet recruiting
- Hepatocellular Carcinoma
- iNKT Cells
- +2 more
-
Beijing, Beijing, ChinaBeijing Youan Hospital,Capital Medical University
Jul 24, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Dalpiciclib Isetionate Tablets, Camrelizumab
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023
Oropharyngeal Cancer Trial in Shanghai (Toxicities reduced treatment, Conventional treatment)
Recruiting
- Oropharyngeal Cancer
- Toxicities reduced treatment
- Conventional treatment
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Nov 26, 2023
Gastric Cancer, GastroEsophageal Cancer Trial in Wuhan (Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound
Active, not recruiting
- Gastric Cancer
- GastroEsophageal Cancer
- Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
- Albumin-bound Paclitaxel
-
Wuhan, Hubei, ChinaTongji hospital of Tongji Medical College, Huazhong University o
Jan 21, 2023
Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- BTK inhibitor
- PD-1 inhibitor
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023
Advanced Solid Tumor Trial in Xuzhou (Oncolytic Virus Injection(Revottack)+PD-1)
Not yet recruiting
- Advanced Solid Tumor
- Oncolytic Virus Injection（Revottack）+PD-1
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Dec 1, 2022
Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel),
Not yet recruiting
- Nasopharyngeal Carcinoma
- Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
- +3 more
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Sep 17, 2022
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Wuhan (drug, procedure, radiation)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Neoadjuvant Therapy
- 3cycles (Toripalimab + cetuximab)
- +2 more
-
Wuhan, Hebei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Aug 6, 2023
Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma Trial in Guangzhou (PD-1 inhibitor, PD-1
Recruiting
- Classical Hodgkin Lymphoma
- Refractory or Relapsed Classical Hodgkin Lymphoma
- PD-1 inhibitor
- PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
-
Guangzhou, Guangdong, China
- +2 more
May 6, 2022
Locally Advanced Rectal Cancer Trial in Beijing (capecitabine, tislelizumab, thymalfasin)
Not yet recruiting
- Locally Advanced Rectal Cancer
- capecitabine
- +3 more
-
Beijing, China
- +1 more
Sep 21, 2023
Locally Advanced Colon Cancer Trial (Serplulimab, short-term radiotherapy, Oxaliplatin)
Not yet recruiting
- Locally Advanced Colon Cancer
- Serplulimab
- +3 more
- (no location specified)
Feb 16, 2023
Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,
Not yet recruiting
- Advanced Lung Squamous Cell Carcinoma
- low-dose radiation therapy and stereotactic body radiation therapy
- +2 more
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
Nov 13, 2023
Brain Metastases Trial in Houston (Niraparib, Dostarlimab)
Not yet recruiting
- Brain Metastases
-
Houston, TexasM D Anderson Cancer Center
Jan 17, 2023
Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor Trial (PD-1 inhibitor+GP, GP)
Not yet recruiting
- Nasopharyngeal Carcinoma
- +2 more
- PD-1 inhibitor+GP
- GP
- (no location specified)
Jul 1, 2022
Esophageal Tumors Trial (radiation, drug, biological)
Not yet recruiting
- Esophageal Neoplasms
- Radiation
- +2 more
- (no location specified)
Oct 16, 2023